List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8015715/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers. Ocular Immunology and Inflammation, 2023, 31, 1707-1715.	1.0	Ο
2	Oxidative and antioxidative stress markers in dry eye disease: A systematic review and metaâ€analysis. Acta Ophthalmologica, 2022, 100, 45-57.	0.6	20
3	Update on fungal keratitis in France: a case–control study. Acta Ophthalmologica, 2022, 100, 159-163.	0.6	7
4	Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases. Ocular Immunology and Inflammation, 2022, 30, 1945-1955.	1.0	2
5	Association of Dry Eye with Laryngopharyngeal Reflux in Clinical Practice. Current Eye Research, 2022, 47, 214-219.	0.7	7
6	An overview of current alternative models in the context of ocular surface toxicity. Journal of Applied Toxicology, 2022, 42, 718-737.	1.4	4
7	Association of Dry Eye with Laryngopharyngeal Reflux in Clinical Practice. Reply to Lechien et al. Current Eye Research, 2022, 47, 327-328.	0.7	0
8	A multi-center study evaluating the correlation between meibomian gland dysfunction and depressive symptoms. Scientific Reports, 2022, 12, 443.	1.6	1
9	Effect of artificial tears on dynamic optical quality in patients with dry eye disease. BMC Ophthalmology, 2022, 22, 64.	0.6	2
10	The Dual Effect of Rho-Kinase Inhibition on Trabecular Meshwork Cells Cytoskeleton and Extracellular Matrix in an In Vitro Model of Glaucoma. Journal of Clinical Medicine, 2022, 11, 1001.	1.0	16
11	Shhedding New Light on the Role of Hedgehog Signaling in Corneal Wound Healing. International Journal of Molecular Sciences, 2022, 23, 3630.	1.8	4
12	Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model. Journal of Neuroinflammation, 2022, 19, 63.	3.1	11
13	Driving behaviour and visual compensation in glaucoma patients: Evaluation on a driving simulator. Clinical and Experimental Ophthalmology, 2022, , .	1.3	1
14	Proteomic Analysis of Tears and Conjunctival Cells Collected with Schirmer Strips Using timsTOF Pro: Preanalytical Considerations. Metabolites, 2022, 12, 2.	1.3	16
15	Identification of new Omega-3 very long chain poly-unsaturated fatty acids in meibomian gland secretions. Biochimie, 2022, 203, 3-10.	1.3	2
16	Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Progress in Retinal and Eye Research, 2021, 83, 100916.	7.3	183
17	The role of Ahmed glaucoma valve in the management of refractory glaucoma: Long-term outcomes and complications. European Journal of Ophthalmology, 2021, 31, 2383-2389.	0.7	9
18	Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review. Ocular Immunology and Inflammation, 2021, 29, 1606-1615.	1.0	2

#	Article	IF	CITATIONS
19	Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride. British Journal of Ophthalmology, 2021, 105, 608-613.	2.1	15
20	Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction. European Journal of Ophthalmology, 2021, 31, 112-119.	0.7	39
21	The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opinion on Drug Safety, 2021, 20, 453-466.	1.0	16
22	Follow-Up of Nonarteritic Anterior Ischemic Optic Neuropathy With Optical Coherence Tomography Angiography. , 2021, 62, 42.		10
23	Excimer laser programming of refractive astigmatism vs. anterior corneal astigmatism in the case of ocular residual astigmatism (ORA). Journal Francais D'Ophtalmologie, 2021, 44, 189-195.	0.2	4
24	Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis. Advances in Therapy, 2021, 38, 3019-3031.	1.3	13
25	The Enduring Experience in Dry Eye Diagnosis: A Non-Interventional Study Comparing the Experiences of Patients Living With and Without SjA¶gren's Syndrome. Ophthalmology and Therapy, 2021, 10, 321-335.	1.0	0
26	Capsazepine decreases corneal pain syndrome in severe dry eye disease. Journal of Neuroinflammation, 2021, 18, 111.	3.1	27
27	Assessing the correlation between swept-source optical coherence tomography lens density pattern analysis and best-corrected visual acuity in patients with cataracts. BMJ Open Ophthalmology, 2021, 6, e000730.	0.8	1
28	Corneal Changes in Acanthamoeba Keratitis at Various Levels of Severity: An In Vivo Confocal Microscopic Study. Translational Vision Science and Technology, 2021, 10, 10.	1.1	8
29	Cystic maculopathy of the inner nuclear layer in glaucoma patients. Journal Francais D'Ophtalmologie, 2021, 44, 786-791.	0.2	2
30	Deepening of lipidome annotation by associating cross-metathesis reaction with mass spectrometry: application to an in vitro model of corneal toxicity. Analytical and Bioanalytical Chemistry, 2021, 413, 4825-4836.	1.9	3
31	Flexible silicone artificial iris in cases of aniridia and iris deficiencies. Journal Francais D'Ophtalmologie, 2021, 44, 1387-1395.	0.2	1
32	PreserFlo MicroShunt® exposure: a case series. BMC Ophthalmology, 2021, 21, 273.	0.6	9
33	Evaluation of pterygium severity with en face anterior segment optical coherence tomography and correlations with in vivo confocal microscopy. Journal Francais D'Ophtalmologie, 2021, 44, 1362-1369.	0.2	2
34	Glare and Mobility Performance in Glaucoma. Journal of Glaucoma, 2021, Publish Ahead of Print, 963-970.	0.8	2
35	AOP and IATA applied to ocular surface toxicity. Regulatory Toxicology and Pharmacology, 2021, 125, 105021.	1.3	4
36	The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders. Survey of Ophthalmology, 2021, 66, 907-925.	1.7	56

#	Article	IF	CITATIONS
37	Ocular surface assessment in times of sanitary crisis: What lessons and solutions for the present and the future?. European Journal of Ophthalmology, 2021, 31, 807-816.	0.7	2
38	The trabecular meshwork in glaucoma: An inflammatory trabeculopathy?. Journal Francais D'Ophtalmologie, 2021, 44, e497-e517.	0.2	8
39	Corneal Nerve Abnormalities in Painful Dry Eye Disease Patients. Biomedicines, 2021, 9, 1424.	1.4	12
40	Comparison of Two Experimental Mouse Dry Eye Models through Inflammatory Gene Set Enrichment Analysis Based on a Multiplexed Transcriptomic Approach. International Journal of Molecular Sciences, 2021, 22, 10770.	1.8	4
41	IgE Ratio in Tears: A Predictive Tool of Ocular Allergic Inflammation. Ocular Immunology and Inflammation, 2020, 28, 775-785.	1.0	5
42	Dry Eye Etiology: Focus on Friction. Klinische Monatsblatter Fur Augenheilkunde, 2020, 237, 1235-1236.	0.3	5
43	Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro. Toxicology Letters, 2020, 319, 74-84.	0.4	27
44	Autologous Serum Eye Drops versus Artificial Tear Drops for Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ophthalmic Research, 2020, 63, 443-451.	1.0	23
45	Acute ischemic optic nerve disease: Pathophysiology, clinical features and management. Journal Francais D'Ophtalmologie, 2020, 43, e41-e54.	0.2	5
46	Correlations Between Subjective Evaluation of Quality of Life, Visual Field Loss, and Performance in Simulated Activities of Daily Living in Glaucoma Patients. Journal of Glaucoma, 2020, 29, 970-974.	0.8	18
47	Topical treatment with a mu opioid receptor agonist alleviates corneal allodynia and corneal nerve sensitization in mice. Biomedicine and Pharmacotherapy, 2020, 132, 110794.	2.5	12
48	Is the Xen® Gel Stent really minimally invasive?. American Journal of Ophthalmology Case Reports, 2020, 19, 100850.	0.4	7
49	Lipidomic analysis of human corneal epithelial cells exposed to ocular irritants highlights the role of phospholipid and sphingolipid metabolisms in detergent toxicity mechanisms. Biochimie, 2020, 178, 148-157.	1.3	14
50	The trabecular meshwork: Structure, function and clinical implications. A review of the literature. Journal Francais D'Ophtalmologie, 2020, 43, e217-e230.	0.2	65
51	<p>Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments</p> . Clinical Ophthalmology, 2020, Volume 14, 3675-3680.	0.9	17
52	TRPM8: A Therapeutic Target for Neuroinflammatory Symptoms Induced by Severe Dry Eye Disease. International Journal of Molecular Sciences, 2020, 21, 8756.	1.8	22
53	VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Scientific Reports, 2020, 10, 12409.	1.6	48
54	Influence of automated visual field testing on intraocular pressure. BMC Ophthalmology, 2020, 20, 363.	0.6	0

#	Article	IF	CITATIONS
55	Morphological and Functional Changes of Corneal Nerves and Their Contribution to Peripheral and Central Sensory Abnormalities. Frontiers in Cellular Neuroscience, 2020, 14, 610342.	1.8	49
56	Defining Dry Eye from a Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 9271.	1.8	118
57	The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial. Journal of Clinical Medicine, 2020, 9, 3536.	1.0	9
58	Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 355-365.	0.6	19
59	Cataract and glaucoma combined surgery: XEN® gel stent versus nonpenetrating deep sclerectomy, a pilot study. BMC Ophthalmology, 2020, 20, 231.	0.6	8
60	Lipid Annotation by Combination of UHPLC-HRMS (MS), Molecular Networking, and Retention Time Prediction: Application to a Lipidomic Study of In Vitro Models of Dry Eye Disease. Metabolites, 2020, 10, 225.	1.3	16
61	Evaluation of Toluidine Blue-Mediated Photodynamic Therapy for Experimental Bacterial Keratitis in Rabbits. Translational Vision Science and Technology, 2020, 9, 13.	1.1	13
62	Glaucoma: A Degenerative Optic Neuropathy Related to Neuroinflammation?. Cells, 2020, 9, 535.	1.8	59
63	Prevalence of Unknown Ocular Hypertension, Glaucoma Suspects, and Glaucoma in Patients Seen in an Ophthalmology Center in France. Ophthalmic Research, 2020, 63, 295-301.	1.0	8
64	Fast and sustained healing of resistant corneal ulcers using corneal scrubbing and matrix regenerating therapy. European Journal of Ophthalmology, 2020, 31, 112067212092137.	0.7	0
65	Preservativeâ€free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008â€2016. Acta Ophthalmologica, 2020, 98, e876-e881.	0.6	16
66	Lipidomic analysis of epithelial corneal cells following hyperosmolarity and benzalkonium chloride exposure: New insights in dry eye disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158728.	1.2	14
67	In vivo Meibomian gland imaging techniques: A review of the literature. Journal Francais D'Ophtalmologie, 2020, 43, e123-e131.	0.2	6
68	Assessment of corneal epithelial thickness mapping in epithelial basement membrane dystrophy. PLoS ONE, 2020, 15, e0239124.	1.1	12
69	Assessment of patient burden from dry eye disease using a combination of five visual analogue scales and a radar graph: a pilot study of the PENTASCORE. British Journal of Ophthalmology, 2020, , bjophthalmol-2020-317473.	2.1	1
70	Assessment of corneal epithelial thickness mapping in epithelial basement membrane dystrophy. , 2020, 15, e0239124.		0
71	Assessment of corneal epithelial thickness mapping in epithelial basement membrane dystrophy. , 2020, 15, e0239124.		0
72	Assessment of corneal epithelial thickness mapping in epithelial basement membrane dystrophy. , 2020,		0

15, e0239124.

#	Article	IF	CITATIONS
73	Assessment of corneal epithelial thickness mapping in epithelial basement membrane dystrophy. , 2020, 15, e0239124.		Ο
74	The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. European Journal of Ophthalmology, 2019, 29, 210-215.	0.7	31
75	Efficacy of a Topical Heparan Sulfate Mimetic Polymer on Ocular Surface Discomfort in Patients with Cogan's Epithelial Basement Membrane Dystrophy. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 359-365.	0.6	1
76	A review of the efficacy, safety and tolerability of Lacrycon® eye drops for the treatment of dry eye syndrome. Journal Francais D'Ophtalmologie, 2019, 42, 642-654.	0.2	5
77	Long term effect of phacoemulsification on intraocular pressure in patients with medically controlled primary open-angle glaucoma. BMC Ophthalmology, 2019, 19, 149.	0.6	33
78	Optical Coherence Tomography Angiography Evaluation of Conjunctival Vessels During Filtering Surgery. Translational Vision Science and Technology, 2019, 8, 4.	1.1	13
79	In Vitro Effect of Toluidine Blue Antimicrobial Photodynamic Chemotherapy on <i>Staphylococcus epidermidis</i> and <i>Staphylococcus aureus</i> Isolated from Ocular Surface Infection. Translational Vision Science and Technology, 2019, 8, 45.	1.1	13
80	XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literature. Journal Francais D'Ophtalmologie, 2019, 42, e37-e46.	0.2	35
81	Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops. Current Eye Research, 2019, 44, 476-485.	0.7	18
82	Dual enkephalinase inhibitor PL265: a novel topical treatment to alleviate corneal pain and inflammation. Pain, 2019, 160, 307-321.	2.0	22
83	Tear film analysis and evaluation of optical quality: A review of the literature. Journal Francais D'Ophtalmologie, 2019, 42, e21-e35.	0.2	24
84	Implication of Melanopsin and Trigeminal Neural Pathways in Blue Light Photosensitivity in vivo. Frontiers in Neuroscience, 2019, 13, 497.	1.4	27
85	Correlation of clinical symptoms and signs with conjunctival gene expression in primary Sjögren syndrome dry eye patients. Ocular Surface, 2019, 17, 516-525.	2.2	21
86	Changes in choroidal thickness and optic nerve head morphology after filtering surgery: nonpenetrating deep sclerectomy versus trabeculectomy. BMC Ophthalmology, 2019, 19, 24.	0.6	5
87	LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS. Innovation in Aging, 2019, 3, S264-S264.	0.0	0
88	Iridoplasty for plateau iris syndrome: a systematic review. BMJ Open Ophthalmology, 2019, 4, e000340.	0.8	5
89	Occurence of bilateral keratoconus and basal laminar drusen: A chance association or a true relationship?. Journal Francais D'Ophtalmologie, 2019, 42, e479-e481.	0.2	1
90	The Role of Meibography in the Diagnosis of Meibomian Gland Dysfunction in Ocular Surface Diseases. Translational Vision Science and Technology, 2019, 8, 6.	1.1	16

#	Article	IF	CITATIONS
91	Chronic dry eye induced corneal hypersensitivity, neuroinflammatory responses, and synaptic plasticity in the mouse trigeminal brainstem. Journal of Neuroinflammation, 2019, 16, 268.	3.1	70
92	Management of dry eye disease to optimize cataract surgery outcomes: Two tables for a daily clinical practice. Journal Francais D'Ophtalmologie, 2019, 42, 907-912.	0.2	13
93	Role of corneal nerves in ocular surface homeostasis and disease. Acta Ophthalmologica, 2019, 97, 137-145.	0.6	125
94	Reconsidering the central role of mucins in dry eye and ocular surface diseases. Progress in Retinal and Eye Research, 2019, 71, 68-87.	7.3	78
95	Effects of corneal injury on ciliary nerve fibre activity and corneal nociception in mice: A behavioural and electrophysiological study. European Journal of Pain, 2019, 23, 589-602.	1.4	22
96	In vivo confocal microscopy classification in the diagnosis of meibomian gland dysfunction. Eye, 2019, 33, 754-760.	1.1	19
97	Blue light exposure in vitro causes toxicity to trigeminal neurons and glia through increased superoxide and hydrogen peroxide generation. Free Radical Biology and Medicine, 2019, 131, 27-39.	1.3	36
98	Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. British Journal of Ophthalmology, 2019, 103, 125-131.	2.1	35
99	Controlled Adverse Environment Chambers in Dry Eye Research. Current Eye Research, 2018, 43, 445-450.	0.7	20
100	Expression of cytokines in aqueous humor from fungal keratitis patients. BMC Ophthalmology, 2018, 18, 105.	0.6	20
101	Neurotrophic keratopathy. Progress in Retinal and Eye Research, 2018, 66, 107-131.	7.3	250
102	Clinical impact of inflammation in dry eye disease: proceedings of the <scp>ODISSEY</scp> group meeting. Acta Ophthalmologica, 2018, 96, 111-119.	0.6	100
103	International publication trends in dry eye disease research: A bibliometric analysis. Ocular Surface, 2018, 16, 173-179.	2.2	51
104	Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases. Journal of Glaucoma, 2018, 27, 1105-1111.	0.8	25
105	Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study. Clinical Ophthalmology, 2018, Volume 12, 2499-2508.	0.9	15
106	Correlation Between Visual Function and Performance of Simulated Daily Living Activities in Glaucomatous Patients. Journal of Glaucoma, 2018, 27, 1017-1024.	0.8	24
107	Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study. Clinical Therapeutics, 2018, 40, 1894-1906.	1.1	13
108	Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naÃ <sup>-</sup> ve patients and patients intolerant to other hypotensive medications. Journal Francais D'Ophtalmologie, 2018, 41, 945-954.	0.2	16

#	Article	IF	CITATIONS
109	Conjunctival Inflammatory Gene Expression Profiling in Dry Eye Disease: Correlations With HLA-DRA and HLA-DRB1. Frontiers in Immunology, 2018, 9, 2271.	2.2	27
110	Spontaneous Eye Blink Patterns in Dry Eye: Clinical Correlations. , 2018, 59, 5149.		45
111	Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clinical Ophthalmology, 2018, Volume 12, 289-299.	0.9	18
112	The Efficacy of Deep Sclerectomy on Posture-induced Intraocular Pressure Changes. Journal of Glaucoma, 2018, 27, 617-621.	0.8	10
113	Formaldehyde Gas Exposure Increases Inflammation in an In Vitro Model of Dry Eye. Toxicological Sciences, 2018, 165, 108-117.	1.4	11
114	Proinflammatory Markers, Chemokines, and Enkephalin in Patients Suffering from Dry Eye Disease. International Journal of Molecular Sciences, 2018, 19, 1221.	1.8	45
115	Blue light phototoxicity toward human corneal and conjunctival epithelial cells in basal and hyperosmolar conditions. Free Radical Biology and Medicine, 2018, 126, 27-40.	1.3	55
116	Impact of Dry Eye Disease on Vision Quality: An Optical Quality Analysis System Study. Translational Vision Science and Technology, 2018, 7, 5.	1.1	32
117	Early recovery of quality of vision and optical performance after refractive surgery: Small-incision lenticule extraction versus laser in situ keratomileusis. Journal of Cataract and Refractive Surgery, 2018, 44, 1073-1079.	0.7	25
118	Retinal and Choroidal Microvasculature in Nonarteritic Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study. , 2018, 59, 870.		61
119	In vivo confocal microscopy evaluation of ocular and cutaneous alterations in patients with rosacea. British Journal of Ophthalmology, 2017, 101, bjophthalmol-2015-308110.	2.1	25
120	Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocular Surface, 2017, 15, 179-192.	2.2	107
121	Keratitis in Dry Eye Disease and Topical Ciclosporin A. Ocular Immunology and Inflammation, 2017, 25, 577-586.	1.0	18
122	Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma. Toxicology in Vitro, 2017, 41, 21-29.	1.1	36
123	Patients' perception of DED and its relation with time to diagnosis and quality of life: an international and multilingual survey. British Journal of Ophthalmology, 2017, 101, 1100-1105.	2.1	22
124	Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye. Eye, 2017, 31, 1409-1416.	1.1	26
125	Ocular Surface and External Filtration Surgery: Mutual Relationships. Developments in Ophthalmology, 2017, 59, 67-79.	0.1	38
126	Clinical Evaluation of an Oil-Based Lubricant Eyedrop in Dry Eye Patients with Lipid Deficiency. European Journal of Ophthalmology, 2017, 27, 122-128.	0.7	14

#	Article	IF	CITATIONS
127	Effect of Surgical Intraocular Pressure Lowering on Peripapillary and Macular Vessel Density in Glaucoma Patients: An Optical Coherence Tomography Angiography Study. Journal of Glaucoma, 2017, 26, 466-472.	0.8	36
128	Pan-European survey of the topical ocular use of cyclosporine A. Journal Francais D'Ophtalmologie, 2017, 40, 187-195.	0.2	18
129	A Randomized, Controlled Study of the Efficacy and Safety of a New Eyedrop Formulation for Moderate to Severe Dry Eye Syndrome. European Journal of Ophthalmology, 2017, 27, 1-9.	0.7	45
130	A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye. European Journal of Ophthalmology, 2017, 27, 520-530.	0.7	65
131	Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye. British Journal of Ophthalmology, 2017, 101, 487-492.	2.1	12
132	Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. Ocular Surface, 2017, 15, 169-178.	2.2	57
133	RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconjugate Journal, 2017, 34, 325-338.	1.4	55
134	Hyperosmolarity and Benzalkonium Chloride Differently Stimulate Inflammatory Markers in Conjunctiva-Derived Epithelial Cells in vitro. Ophthalmic Research, 2017, 58, 40-48.	1.0	27
135	Increased corneal subâ€basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A. Clinical and Experimental Ophthalmology, 2017, 45, 455-463.	1.3	39
136	Role of laser peripheral iridotomy in pigmentary glaucoma and pigment dispersion syndrome: A review of the literature. Journal Francais D'Ophtalmologie, 2017, 40, e315-e321.	0.2	7
137	TFOS DEWS II iatrogenic report. Ocular Surface, 2017, 15, 511-538.	2.2	304
138	Efficacy of 2 Trabecular Micro-Bypass Stents During Phacoemulsification for Mild to Advanced Primary Open-angle Glaucoma Controlled With Topical Hypotensive Medications. Journal of Glaucoma, 2017, 26, 1149-1154.	0.8	13
139	One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. European Journal of Ophthalmology, 2017, 27, 678-685.	0.7	55
140	Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease. , 2017, 58, 2438.		36
141	The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells. , 2017, 58, 2406.		79
142	A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study. , 2017, 58, 2275.		42
143	In vivo imaging of palisades of Vogt in dry eye versus normal subjects using en-face spectral-domain optical coherence tomography. PLoS ONE, 2017, 12, e0187864.	1.1	7
144	Author's Reply to: "Concerns Over: Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease― European Journal of Ophthalmology, 2017, 27, e194-e195.	0.7	2

#	Article	IF	CITATIONS
145	Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells. , 2016, 57, 1816.		32
146	Ocular Surface Epithelial Thickness Evaluation in Dry Eye Patients: Clinical Correlations. Journal of Ophthalmology, 2016, 2016, 1-8.	0.6	33
147	Optic Disc Vascularization in Glaucoma: Value of Spectral-Domain Optical Coherence Tomography Angiography. Journal of Ophthalmology, 2016, 2016, 1-9.	0.6	107
148	Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmologica, 2016, 94, 499-506.	0.6	45
149	A Severe Case of Pigmentary Glaucoma in a Child With a Family History of Pigment Dispersion Syndrome. Journal of Glaucoma, 2016, 25, e745-e747.	0.8	4
150	Evaluation of Blebs After Filtering Surgery With En-Face Anterior-Segment Optical Coherence Tomography: A Pilot Study. Journal of Glaucoma, 2016, 25, e550-e558.	0.8	23
151	Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial. European Journal of Ophthalmology, 2016, 26, 287-296.	0.7	137
152	Efficacy and Safety of a Cationic Emulsion in the Treatment of Moderate to Severe Dry Eye Disease: A Randomized Controlled Study. European Journal of Ophthalmology, 2016, 26, 546-555.	0.7	29
153	Elimination of blinding trachoma in China. Journal Francais D'Ophtalmologie, 2016, 39, 836-842.	0.2	3
154	Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2322-2332.	1.9	15
155	Potential Role of In Vivo Confocal Microscopy for Imaging Corneal Nerves in Transthyretin Familial Amyloid Polyneuropathy. JAMA Ophthalmology, 2016, 134, 983.	1.4	52
156	Bilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the rat. Journal of Neuroinflammation, 2016, 13, 44.	3.1	51
157	Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. British Journal of Ophthalmology, 2016, 100, 300-306.	2.1	332
158	In vivo characterization of lamina cribrosa pore morphology in primary open-angle glaucoma. Journal Francais D'Ophtalmologie, 2016, 39, 265-271.	0.2	16
159	Ocular inflammation induces trigeminal pain, peripheral and central neuroinflammatory mechanisms. Neurobiology of Disease, 2016, 88, 16-28.	2.1	78
160	In Vitro Inhibition of NFAT5-Mediated Induction of CCL2 in Hyperosmotic Conditions by Cyclosporine and Dexamethasone on Human HeLa-Modified Conjunctiva-Derived Cells. PLoS ONE, 2016, 11, e0159983.	1.1	22
161	Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. Stem Cell Research and Therapy, 2015, 6, 177.	2.4	70
162	The Measurement of Bulbar Hyperemia: Challenges and Pitfalls. European Journal of Ophthalmology, 2015, 25, 273-279.	0.7	20

#	Article	IF	CITATIONS
163	Evaluation of Optical Coherence Tomography Meibography in Patients With Obstructive Meibomian Gland Dysfunction. Cornea, 2015, 34, 1193-1199.	0.9	46
164	Dynamic Change of Optical Quality in Patients With Dry Eye Disease. , 2015, 56, 2848.		39
165	Cyclocoagulation of the Ciliary Bodies by High-Intensity Focused Ultrasound: A 12-Month Multicenter Study. Investigative Ophthalmology and Visual Science, 2015, 56, 1089-1096.	3.3	66
166	Photophobia and Corneal Crystal Density in Nephropathic Cystinosis: An In Vivo Confocal Microscopy and Anterior-Segment Optical Coherence Tomography Study. , 2015, 56, 3218.		35
167	Patient satisfaction with glaucoma therapy: reality or myth?. Clinical Ophthalmology, 2015, 9, 785.	0.9	57
168	Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments. Current Eye Research, 2015, 40, 40-47.	0.7	7
169	<i>In vivo</i> confocal microscopy as a novel and reliable tool for the diagnosis of <i>Demodex</i> eyelid infestation. British Journal of Ophthalmology, 2015, 99, 336-341.	2.1	74
170	Modulation of Wound Healing. , 2015, , 894-905.		2
171	Combined 3DISCO clearing method, retrograde tracer and ultramicroscopy to map corneal neurons in a whole adult mouse trigeminal ganglion. Experimental Eye Research, 2015, 139, 136-143.	1.2	42
172	In vivo confocal microscopy and spectral domain anterior segment OCT in Lisch epithelial corneal dystrophy. Journal Francais D'Ophtalmologie, 2015, 38, e151-e153.	0.2	3
173	Dry Eye Disease after Refractive Surgery. Ophthalmology, 2015, 122, 669-676.	2.5	213
174	Glaucoma patient satisfaction regarding tolerance to their prostaglandin treatment: results from the GOAL (Glaucoma patients treated with prOstaglandins; sAtisfaction evaLuation) survey in Europe. Acta Ophthalmologica, 2015, 93, n/a-n/a.	0.6	0
175	En-face Optical Coherence Tomography as a Novel Tool for Exploring the Ocular Surface: A Pilot Comparative Study to Conventional B-Scans and inÂVivo Confocal Microscopy. Ocular Surface, 2014, 12, 285-306.	2.2	19
176	Can breast implants be responsible for dry eye?. Eye, 2014, 28, 633-634.	1.1	1
177	Open-angle glaucoma secondary to Cushing syndrome related to an adrenal adenoma: Case report. Journal Francais D'Ophtalmologie, 2014, 37, e169.	0.2	5
178	Reis-Bücklers Corneal Dystrophy: A Reappraisal Using in vivo and ex vivo Imaging Techniques. Ophthalmic Research, 2014, 51, 187-195.	1.0	12
179	<i>In Vivo</i> Confocal Microscopy of the Ocular Surface: From Bench to Bedside. Current Eye Research, 2014, 39, 213-231.	0.7	184
180	Rethinking Dry Eye Disease: A Perspective on Clinical Implications. Ocular Surface, 2014, 12, S1-S31.	2.2	189

#	Article	IF	CITATIONS
181	Prospective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy Trial. Advances in Therapy, 2014, 31, 189-201.	1.3	150
182	A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: The Cystadrops OCT-1 study. Molecular Genetics and Metabolism, 2014, 111, 314-320.	0.5	53
183	Evaluation of an eyelid warming device (Blephasteam®) for the management of ocular surface diseases in France: The ESPOIR study. Journal Francais D'Ophtalmologie, 2014, 37, 763-772.	0.2	22
184	Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease–ÂA randomised comparative study. Journal Francais D'Ophtalmologie, 2014, 37, 589-598.	0.2	37
185	Femtosecond and excimer laser-assisted endothelial keratoplasty (FELEK): A new technique of endothelial transplantation. Journal Francais D'Ophtalmologie, 2014, 37, 211-219.	0.2	8
186	Diagnosing the severity of dry eye: a clear and practical algorithm. British Journal of Ophthalmology, 2014, 98, 1168-1176.	2.1	167
187	Aberrométrie et film lacrymal. , 2014, , 25-36.		0
188	Imagerie en microscopie confocale in vivo. , 2014, , 99-108.		0
189	Nutritional, lifestyle and environmental factors in ocular hypertension and primary open-angle glaucoma: an exploratory case-control study. Acta Ophthalmologica, 2013, 91, 505-513.	0.6	63
190	Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 4039-4049.	1.9	47
191	Influence of sutureless 23-gauge sclerotomy architecture on postoperative intraocular pressure decrease: results of a multivariate analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1285-1292.	1.0	8
192	Dry Eye and Biomarkers: Present and Future. Current Ophthalmology Reports, 2013, 1, 65-74.	0.5	16
193	Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting. Ocular Surface, 2013, 11, 246-258.	2.2	359
194	RGTA-based matrix therapy in severe experimental corneal lesions: Safety and efficacy studies. Journal Francais D'Ophtalmologie, 2013, 36, 740-747.	0.2	44
195	Corneal imaging of intrastromal femtosecond laser treatment for presbyopia (Intracor®). Journal Francais D'Ophtalmologie, 2013, 36, 669-676.	0.2	3
196	Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance. Journal Francais D'Ophtalmologie, 2013, 36, 316-323.	0.2	6
197	From pathogenic considerations to a simplified decision-making schema in dry eye disease. Journal Francais D'Ophtalmologie, 2013, 36, 543-547.	0.2	8
198	The Impact of Dry Eye Disease on Visual Performance While Driving. American Journal of Ophthalmology, 2013, 156, 184-189.e3.	1.7	77

#	Article	IF	CITATIONS
199	Influence of corneal biomechanical properties on surgically induced astigmatism in cataract surgery. Journal of Cataract and Refractive Surgery, 2013, 39, 1204-1210.	0.7	55
200	Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. British Journal of Ophthalmology, 2013, 97, 196-200.	2.1	82
201	Corneal Nerve Structure and Function in Patients With Non-Sjögren Dry Eye: Clinical Correlations. , 2013, 54, 5144.		161
202	Comparison of 23â€gauge sutureless sclerotomy architecture and clinical outcomes in macular and nonâ€macular surgery using spectralâ€domain optical coherence tomography. Acta Ophthalmologica, 2013, 91, e203-10.	0.6	5
203	A new technique of endothelial graft: the femtosecond and excimer lasers-assisted endothelial keratoplasty (FELEK). Acta Ophthalmologica, 2013, 91, e497-e499.	0.6	2
204	Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study. British Journal of Ophthalmology, 2013, 97, 1399-1403.	2.1	152
205	Prevalence and Risk Factors for Ocular Surface Disease among Patients Treated over the Long Term for Glaucoma or Ocular Hypertension. European Journal of Ophthalmology, 2013, 23, 47-54.	0.7	79
206	Effects of Benzalkonium Chloride on THP-1 Differentiated Macrophages In Vitro. PLoS ONE, 2013, 8, e72459.	1.1	27
207	Advance in Corneal Imaging. , 2013, , 53-70.		0
208	How inflammatory reactions affect POAG topical and surgical treatment?. Acta Ophthalmologica, 2013, 91, 0-0.	0.6	0
209	Corneal nerve structure and function in patients with non-Sjögren dry eye. Acta Ophthalmologica, 2013, 91, 0-0.	0.6	0
210	Ocular Surface and External Filtration Surgery: Mutual Relationships. Developments in Ophthalmology, 2012, 50, 64-78.	0.1	29
211	Reduced in vivo Ocular Surface Toxicity with Polyquad-Preserved Travoprost versus Benzalkonium-Preserved Travoprost or Latanoprost Ophthalmic Solutions. Ophthalmic Research, 2012, 48, 89-101.	1.0	49
212	The Relationship between Subbasal Nerve Morphology and Corneal Sensation in Ocular Surface Disease. , 2012, 53, 4926.		153
213	In Vitro and In Vivo Evaluation of a Preservative-Free Cationic Emulsion of Latanoprost in Corneal Wound Healing Models. Cornea, 2012, 31, 1319-1329.	0.9	31
214	Tear Film Osmolarity in Patients Treated for Glaucoma or Ocular Hypertension. Cornea, 2012, 31, 994-999.	0.9	66
215	CX3CL1 expression in the conjunctiva is involved in immune cell trafficking during toxic ocular surface inflammation. Mucosal Immunology, 2012, 5, 702-711.	2.7	20
216	Appraisal of Patient-Reported Outcome Instruments Available for Randomized Clinical Trials in Dry Eye: Revisiting the Standards. Ocular Surface, 2012, 10, 84-99.	2.2	30

#	Article	IF	CITATIONS
217	Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. Journal Francais D'Ophtalmologie, 2012, 35, 412-419.	0.2	45
218	Tear Film Aberration Dynamics and Vision-Related Quality of Life in Patients with Dry Eye Disease. Ophthalmology, 2012, 119, 1811-1818.	2.5	128
219	A New Safety Concern for Glaucoma Treatment Demonstrated by Mass Spectrometry Imaging of Benzalkonium Chloride Distribution in the Eye, an Experimental Study in Rabbits. PLoS ONE, 2012, 7, e50180.	1.1	92
220	Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. European Journal of Ophthalmology, 2012, 22, 751-761.	0.7	67
221	In Vitro and In Vivo Comparative Toxicological Study of a New Preservative-Free Latanoprost Formulation. , 2012, 53, 8172.		39
222	In Vitro Interactions between Peripheral Blood Lymphocytes and the Wong-Kilbourne Derivative of Chang Conjunctival Cells. , 2012, 53, 1492.		0
223	Conjunctiva-Associated Lymphoid Tissue (CALT) Reactions to Antiglaucoma Prostaglandins with or without BAK-Preservative in Rabbit Acute Toxicity Study. PLoS ONE, 2012, 7, e33913.	1.1	31
224	CXCR3 Antagonism of SDF-1(5-67) Restores Trabecular Function and Prevents Retinal Neurodegeneration in a Rat Model of Ocular Hypertension. PLoS ONE, 2012, 7, e37873.	1.1	26
225	Anterior Segment OCT Imaging. Biological and Medical Physics Series, 2012, , 125-138.	0.3	1
226	Blockade of the chemokine receptor CXCR3 lowers intraocular pressure and prevents retinal degeneration in an animal model of glaucoma. Acta Ophthalmologica, 2012, 90, 0-0.	0.6	0
227	Therapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental system. Molecular Vision, 2012, 18, 317-29.	1.1	37
228	Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Molecular Vision, 2012, 18, 851-63.	1.1	60
229	Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model. Molecular Vision, 2012, 18, 2195-204.	1.1	31
230	In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2012, 110, 40-63.	1.4	41
231	The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. , 2011, 52, 2050.		470
232	Comparative <i>In Vitro</i> Toxicology Study of Travoprost Polyquad-preserved, Travoprost BAK-preserved, and Latanoprost BAK-preserved Ophthalmic Solutions on Human Conjunctival Epithelial Cells. Current Eye Research, 2011, 36, 979-988.	0.7	29
233	<i>In Vitro</i> Comparative Toxicology of Polyquad-Preserved and Benzalkonium Chloride-Preserved Travoprost/Timolol Fixed Combination and Latanoprost/Timolol Fixed Combination. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 273-280.	0.6	32
234	Tear Osmolarity in the Diagnosis and Management of Dry Eye Disease. American Journal of Ophthalmology, 2011, 151, 792-798.e1.	1.7	512

#	Article	IF	CITATIONS
235	EMMPRIN Modulates Epithelial Barrier Function through a MMP–Mediated Occludin Cleavage. American Journal of Pathology, 2011, 179, 1278-1286.	1.9	49
236	Spectrofluorometry assays for oxidative stress and apoptosis, with cell viability on the same microplates: A multiparametric analysis and quality control. Toxicology in Vitro, 2011, 25, 1089-1096.	1.1	11
237	Fungal keratitis in France. Acta Ophthalmologica, 2011, 89, e215-e216.	0.6	14
238	A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmologica, 2011, 89, e591-e597.	0.6	115
239	Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clinical Ophthalmology, 2011, 5, 1575.	0.9	29
240	Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clinical Ophthalmology, 2011, 5, 577.	0.9	88
241	Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Advances in Therapy, 2011, 28, 311-325.	1.3	40
242	Diagnosis of fungal keratitis by in vivo confocal microscopy: a case report. Eye, 2011, 25, 956-958.	1.1	4
243	Ocular Surface Epithelial Thickness Evaluation with Spectral-Domain Optical Coherence Tomography. , 2011, 52, 9116.		120
244	Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. British Journal of Ophthalmology, 2011, 95, 869-875.	2.1	75
245	Abnormal corneal nerves in a patient with Lyme disease. Eye, 2011, 25, 1524-1525.	1.1	1
246	Dynamic corneal wavefront aberrations and quality of vision in patients with dry eye disease. Acta Ophthalmologica, 2011, 89, 0-0.	0.6	0
247	Effects of benzalkonium chloride on antigen presenting cells in vitro. Acta Ophthalmologica, 2011, 89, 0-0.	0.6	0
248	Ocular surface epithelial thickness evaluation with spectralâ€domain optical coherence tomography in patients with dry eye syndrome. Acta Ophthalmologica, 2011, 89, 0-0.	0.6	0
249	Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Molecular Vision, 2011, 17, 745-55.	1.1	22
250	An In Vivo Confocal Microscopy and Impression Cytology Evaluation of Pterygium Activity. Cornea, 2010, 29, 392-399.	0.9	23
251	Modifications in Corneal Biomechanics and Intraocular Pressure After Deep Sclerectomy. Journal of Glaucoma, 2010, 19, 252-256.	0.8	25
252	Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 2010, 29, 312-334.	7.3	787

#	Article	IF	CITATIONS
253	Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmology, 2010, 10, 10.	0.6	7
254	First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmology, 2010, 10, 4.	0.6	16
255	Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a survey. Clinical Ophthalmology, 2010, 4, 731.	0.9	19
256	Live Conjunctiva-Associated Lymphoid Tissue Analysis in Rabbit under Inflammatory Stimuli Using In Vivo Confocal Microscopy. , 2010, 51, 1008.		24
257	Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment. British Journal of Ophthalmology, 2010, 94, 134-135.	2.1	8
258	CHOROIDAL ISCHEMIA SECONDARY TO A DIVING INJURY. Retinal Cases and Brief Reports, 2010, 4, 262-265.	0.3	2
259	Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicology in Vitro, 2010, 24, 276-285.	1.1	37
260	Xal-Ease®: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. European Journal of Ophthalmology, 2009, 19, 949-956.	0.7	28
261	Multiple Endpoint Analysis of the 3D-Reconstituted Corneal Epithelium after Treatment with Benzalkonium Chloride: Early Detection of Toxic Damage. , 2009, 50, 1644.		111
262	Direct epithelial–stromal interaction in corneal wound healing: Role of EMMPRIN/CD147 in MMPs induction and beyond. Progress in Retinal and Eye Research, 2009, 28, 19-33.	7.3	90
263	In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Analysis of the Cornea in Nephropathic Cystinosis. Ophthalmology, 2009, 116, 870-876.	2.5	61
264	In vivo architectural analysis of clear corneal incisions using anterior segment optical coherence tomography. Journal of Cataract and Refractive Surgery, 2009, 35, 444-450.	0.7	42
265	Evaluation of keratic precipitates and corneal endothelium in Fuchs' heterochromic cyclitis by in vivo confocal microscopy. British Journal of Ophthalmology, 2009, 93, 673-677.	2.1	34
266	Contribution of In Vivo Confocal Microscopy to the Diagnosis and Management of Infectious Keratitis. Ocular Surface, 2009, 7, 41-52.	2.2	102
267	The Ocular Surface in Glaucoma. Cornea, 2009, 28, S14-S19.	0.9	17
268	ORBITAL COLOR DOPPLER IMAGING IN EMBOLIC CENTRAL RETINAL ARTERY OBLITERATION ASSOCIATED WITH NEOVASCULAR GLAUCOMA. Retinal Cases and Brief Reports, 2009, 3, 251-252.	0.3	0
269	Efficacy and safety of topical cyclosporine versus vehicle in vernal keratoconjunctivitis in children. Acta Ophthalmologica, 2009, 87, 0-0.	0.6	0
270	In vivo confocal microscopic evaluation of inflammatory changes in the ocular surface. Acta Ophthalmologica, 2009, 87, 0-0.	0.6	0

#	Article	IF	CITATIONS
271	Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Molecular Vision, 2009, 15, 1690-9.	1.1	26
272	Measurement of healthâ€related quality of life with glaucoma: validation of the Glauâ€QoL <sup>©</sup> 36â€item questionnaire. Acta Ophthalmologica, 2008, 86, 71-80.	0.6	76
273	Cytotoxicity of contact lens multipurpose solutions: Role of oxidative stress, mitochondrial activity and P2X7 cell death receptor activation. European Journal of Pharmaceutical Sciences, 2008, 33, 138-145.	1.9	48
274	Severe impairment of health-related quality of life in patients suffering from ocular surface diseases. Journal Francais D'Ophtalmologie, 2008, 31, 369-378.	0.2	34
275	The Ocular Surface of Glaucoma Patients Treated over the Long Term Expresses Inflammatory Markers Related to Both T-Helper 1 and T-Helper 2 Pathways. Ophthalmology, 2008, 115, 109-115.	2.5	179
276	Filtering Blebs and Aqueous Pathway. Ophthalmology, 2008, 115, 1154-1161.e4.	2.5	71
277	Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmologica, 2008, 86, 716-726.	0.6	217
278	Application de l'OCT de segment antérieur dans l'étude des glaucomes. Journal Francais D'Ophtalmologie, 2008, 31, 2S5-2S9.	0.2	3
279	In VivoConfocal Microscopic Grading System for Standardized Corneal Evaluation: Application to Toxic-Induced Damage in Rat. Current Eye Research, 2008, 33, 826-838.	0.7	10
280	Prevalence of vernal keratoconjunctivitis: a rare disease?. British Journal of Ophthalmology, 2008, 92, 1097-1102.	2.1	93
281	Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. British Journal of Ophthalmology, 2008, 92, 1275-1282.	2.1	107
282	<i>In Vitro</i> Effects of Preservative-Free Tafluprost and Preserved Latanoprost, Travoprost, and Bimatoprost in a Conjunctival Epithelial Cell Line. Current Eye Research, 2008, 33, 303-312.	0.7	86
283	Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Molecular Vision, 2008, 14, 204-16.	1.1	43
284	Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Molecular Vision, 2008, 14, 394-402.	1.1	37
285	The corneal endothelium in an endotoxin-induced uveitis model: correlation between in vivo confocal microscopy and immunohistochemistry. Molecular Vision, 2008, 14, 1149-56.	1.1	19
286	Th1- and Th2-related chemokine and chemokine receptor expression on the ocular surface in endotoxin-induced uveitis. Molecular Vision, 2008, 14, 2428-34.	1.1	10
287	In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost. , 2007, 48, 4123.		111
288	In vivo confocal microscopy in fungal keratitis. British Journal of Ophthalmology, 2007, 91, 588-591.	2.1	100

#	Article	IF	CITATIONS
289	Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. British Journal of Ophthalmology, 2007, 91, 29-32.	2.1	113
290	Ocular Symptoms and Signs with Preserved and Preservative-Free Glaucoma Medications. European Journal of Ophthalmology, 2007, 17, 341-349.	0.7	338
291	In Vivo Corneal Confocal Microscopy in Marfan Syndrome. Cornea, 2007, 26, 787-792.	0.9	17
292	Archipelago Keratitis. Ophthalmology, 2007, 114, 2000-2005.	2.5	21
293	Th1 and Th2 Responses on the Ocular Surface in Uveitis Identified by CCR4 and CCR5 Conjunctival Expression. American Journal of Ophthalmology, 2007, 144, 580-585.e2.	1.7	16
294	New Tools for the Evaluation of Toxic Ocular Surface Changes in the Rat. , 2007, 48, 5473.		107
295	Ocular Surface Assessment of Glaucoma Drug Tolerance. European Journal of Ophthalmology, 2007, 17, 18-21.	0.7	1
296	Cytoprotective effect against UV-induced DNA damage and oxidative stress: Role of new biological UV filter. European Journal of Pharmaceutical Sciences, 2007, 30, 203-210.	1.9	44
297	Protein kinase C-ζ mediates retinal degeneration in response to TNF. Journal of Neuroimmunology, 2007, 183, 104-110.	1.1	12
298	Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFNI3 and toxicological profiles. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 534-546.	1.0	22
299	LPS-stimulated inflammation and apoptosis in corneal injury models. Molecular Vision, 2007, 13, 1169-80.	1.1	21
300	Comparison of Toxicological Profiles of Benzalkonium Chloride and Polyquaternium-1: An Experimental Study. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 267-278.	0.6	109
301	In Vivo Corneal Confocal Microscopy Comparison of Intralase Femtosecond Laser and Mechanical Microkeratome for Laser In Situ Keratomileusis. , 2006, 47, 2803.		83
302	Epithelial Basement Membrane Dystrophy. Ophthalmology, 2006, 113, 1301-1308.	2.5	69
303	Bilateral Infectious Ulcers Associated With Atopic Keratoconjunctivitis. Cornea, 2006, 25, 248-250.	0.9	13
304	Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery?. British Journal of Ophthalmology, 2006, 90, 1366-1369.	2.1	21
305	Comparative Anatomy of Laboratory Animal Corneas with a New-Generation High-ResolutionIn VivoConfocal Microscope. Current Eye Research, 2006, 31, 501-509.	0.7	55
306	In vivo confocal microscopy and ex vivo flow cytometry: new tools for assessing ocular inflammation applied to rabbit lipopolysaccharide-induced conjunctivitis. Molecular Vision, 2006, 12, 1392-402.	1.1	19

#	Article	IF	CITATIONS
307	Allergic reaction to topical eyedrops. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 459-463.	1.1	88
308	Radiation-induced apoptosis in the eye structures: a review. Radiation Physics and Chemistry, 2005, 72, 409-418.	1.4	4
309	Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 531-538.	1.0	81
310	The Triple Classification of Dry Eye for Practical Clinical Use. European Journal of Ophthalmology, 2005, 15, 660-667.	0.7	52
311	In Vitro Comparison of Cytoprotective and Antioxidative Effects of Latanoprost, Travoprost, and Bimatoprost on Conjunctiva-Derived Epithelial Cells. , 2005, 46, 4594.		98
312	In Vitro Study of Inflammatory Potential and Toxicity Profile of Latanoprost, Travoprost, and Bimatoprost in Conjunctiva-Derived Epithelial Cells. , 2005, 46, 2444.		162
313	Pathways of Corneal and Ocular Surface Inflammation: A Perspective from the Cullen Symposium. Ocular Surface, 2005, 3, S-131-S-138.	2.2	54
314	Amplifying Factors in Ocular Surface Diseases: Apoptosis. Ocular Surface, 2005, 3, S-194-S-197.	2.2	5
315	Controverse chirurgicale. Journal Francais D'Ophtalmologie, 2005, 28, 55-59.	0.2	1
316	Heidelberg Retina Tomograph II Findings ofAcanthamoebaKeratitis. Ocular Immunology and Inflammation, 2005, 13, 487-492.	1.0	25
317	In Vivo Confocal Microscopy Study of Blebs after Filtering Surgery. Ophthalmology, 2005, 112, 1979.e1-1979.e9.	2.5	119
318	CCR4 and CCR5 expression in conjunctival specimens as differential markers of TH1/ TH2 in ocular surface disorders. Journal of Allergy and Clinical Immunology, 2005, 116, 614-619.	1.5	70
319	The triple classification of dry eye for practical clinical use. European Journal of Ophthalmology, 2005, 15, 660-7.	0.7	12
320	Conjunctival Proinflammatory and Proapoptotic Effects of Latanoprost and Preserved and Unpreserved Timolol: An Ex Vivo and In Vitro Study. Investigative Ophthalmology and Visual Science, 2004, 45, 1360-1368.	3.3	250
321	Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Experimental Eye Research, 2004, 78, 473-481.	1.2	78
322	Comparison of morphological and functional characteristics of primary-cultured human conjunctival epithelium and of Wong–Kilbourne derivative of Chang conjunctival cell line. Experimental Eye Research, 2004, 78, 257-274.	1.2	41
323	Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology, 2004, 111, 2186-2192.	2.5	185
324	In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2003, 241, 1037-1043.	1.0	71

#	Article	IF	CITATIONS
325	In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Current Eye Research, 2003, 27, 253-259.	0.7	24
326	Changes in Medical and Surgical Treatments of Glaucoma between 1997 and 2000 in France. European Journal of Ophthalmology, 2003, 13, 53-60.	0.7	36
327	Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. British Journal of Ophthalmology, 2002, 86, 418-423.	2.1	502
328	Confocal microscopic examination of trabecular meshwork removed during ab externo trabeculectomy. British Journal of Ophthalmology, 2002, 86, 1046-1052.	2.1	37
329	Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. , 2002, 240, 929-935.		39
330	Flow Cytometric Analysis of the Inflammatory Marker HLA DR in Dry Eye Syndrome: Results from 12 Months of Randomized Treatment with Topical Cyclosporin A. Advances in Experimental Medicine and Biology, 2002, 506, 761-769.	0.8	30
331	Relationship between in Vitro Toxicity of Benzalkonium Chloride (BAC) and Preservative-Induced Dry Eye. Advances in Experimental Medicine and Biology, 2002, 506, 697-702.	0.8	15
332	Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Investigative Ophthalmology and Visual Science, 2002, 43, 3409-15.	3.3	60
333	Evaluation of corneal stromal changes in vivo after laser in situ keratomileusis with confocal microscopy. Ophthalmology, 2001, 108, 1744-1750.	2.5	110
334	The Pathology of Dry Eye. Survey of Ophthalmology, 2001, 45, S211-S220.	1.7	271
335	Ocular Surface Changes Induced by Contact Lens Wear. Cornea, 2001, 20, 820-825.	0.9	86
336	Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Investigative Ophthalmology and Visual Science, 2001, 42, 90-5.	3.3	142
337	Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Investigative Ophthalmology and Visual Science, 2001, 42, 642-52.	3.3	152
338	Dry eye: an unexpected inflammatory disease. Archivos De La Sociedad Espanola De Oftalmologia, 2001, 76, 205-6.	0.1	5
339	Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Investigative Ophthalmology and Visual Science, 2001, 42, 2525-33.	3.3	79
340	Comparison of the Effects of Preserved and Unpreserved Formulations of Timolol on the Ocular Surface of Albino Rabbits. Ophthalmic Research, 2000, 32, 3-8.	1.0	128
341	Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238, 900-904.	1.0	37
342	Evaluation of the Toxicity of Benzalkonium Chloride on the Ocular Surface. Cutaneous and Ocular Toxicology, 2000, 19, 105-115.	0.3	6

#	Article	IF	CITATIONS
343	Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology, 2000, 107, 1841-1849.	2.5	155
344	Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Current Eye Research, 2000, 20, 85-94.	0.7	147
345	Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Current Eye Research, 2000, 20, 85-94.	0.7	91
346	Expression of CD40 and CD40 ligand in the human conjunctival epithelium. Investigative Ophthalmology and Visual Science, 2000, 41, 120-6.	3.3	27
347	Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Investigative Ophthalmology and Visual Science, 2000, 41, 1356-63.	3.3	224
348	Fas- and interferon gamma-induced apoptosis in Chang conjunctival cells: further investigations. Investigative Ophthalmology and Visual Science, 2000, 41, 2531-43.	3.3	17
349	Effects of EGb761 and superoxide dismutase in an experimental model of retinopathy generated by intravitreal production of superoxide anion radical. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 58-66.	1.0	17
350	Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology, 1999, 106, 556-563.	2.5	352
351	Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Investigative Ophthalmology and Visual Science, 1999, 40, 619-30.	3.3	226
352	Interferon-gamma induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. Investigative Ophthalmology and Visual Science, 1999, 40, 2199-212.	3.3	38
353	Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Current Eye Research, 1998, 17, 419-425.	0.7	169
354	Expression of Fas-Fas Ligand Antigens and Apoptotic Marker APO2.7 by the Human Conjunctival Epithelium. Positive Correlation with Class II HLA DR Expression in Inflammatory Ocular Surface Disorders. Experimental Eye Research, 1998, 67, 687-697.	1.2	70
355	Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. British Journal of Ophthalmology, 1998, 82, 39-42.	2.1	140
356	CA 19-9ÂELISA test: a new method for studying mucus changes in tears. British Journal of Ophthalmology, 1998, 82, 88-90.	2.1	31
357	Inflammation Measurement and Immunocharacterization of Cell Proliferation in an Experimental Model of Proliferative Vitreoretinopathy. Ophthalmic Research, 1998, 30, 340-350.	1.0	9
358	Immunophenotyping of human dendriform cells from the conjunctival epithelium. Current Eye Research, 1997, 16, 475-481.	0.7	28
359	Flow cytometry in impression cytology specimens. A new method for evaluation of conjunctival inflammation. Investigative Ophthalmology and Visual Science, 1997, 38, 1458-64.	3.3	77
360	Side effects of antiglaucomatous drugs on the ocular surface. Current Opinion in Ophthalmology, 1996, 7, 80-86.	1.3	140

#	Article	IF	CITATIONS
361	Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?. International Journal of Clinical Pharmacology Research, 1996, 16, 29-41.	0.4	20
362	Distribution of Salicylate in Pigmented Rabbit Ocular Tissues After Application of a Prodrug, Sodium Monomethyl Trisilanol Orthohydroxybenzoate: <i>In Vivo</i> and <i>Ex Vivo</i> Studies. Journal of Ocular Pharmacology and Therapeutics, 1995, 11, 83-94.	0.6	0
363	Evaluation of antiproliferative effects of the somatostatin analogue somatuline in a rabbit model of traction retinal detachment*. Fundamental and Clinical Pharmacology, 1995, 9, 357-365.	1.0	5
364	Expression of Inflammatory Membrane Markers by Conjunctival Cells in Chronically Treated Patients with Glaucoma. Ophthalmology, 1994, 101, 454-460.	2.5	119
365	Inhibition of preretinal proliferation by free radical scavengers in an experimental model of tractional retinal detachment. Experimental Eye Research, 1994, 59, 697-706.	1.2	22
366	MHC class II antigen expression by ocular cells in proliferative diabetic retinopathy. Fundamental and Clinical Pharmacology, 1993, 7, 523-530.	1.0	12
367	Growth Factors in Vitreous and Subretinal Fluid Cells from Patients with Proliferative Vitreoretinopathy. Ophthalmic Research, 1993, 25, 52-59.	1.0	90
368	Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens British Journal of Ophthalmology, 1992, 76, 545-549.	2.1	89
369	Induction of experimental proliferative vitreoretinopathy in the rabbit eye by intravitreal injections of fibroblast growth factor. Lens and Eye Toxicity Research, 1992, 9, 505-11.	0.1	1
370	Effects of Gingko biloba extracts in a model of tractional retinal detachment. Lens and Eye Toxicity Research, 1992, 9, 513-9.	0.1	3
371	Immunohistological study of subretinal membranes in age-related macular degeneration. Japanese Journal of Ophthalmology, 1992, 36, 443-51.	0.9	42
372	Acidic FGF and Other Growth Factors in Preretinal Membranes from Patients with Diabetic Retinopathy and Proliferative Vitreoretinopathy. Ophthalmic Research, 1991, 23, 154-161.	1.0	42
373	Transferrin Receptor Expression by Retinal Pigment Epithelial Cells in Proliferative Vitreoretinopathy. JAMA Ophthalmology, 1991, 109, 1195.	2.6	4
374	Immunocytology of Cellular Components in Vitreous and Subretinal Fluid from Patients with Proliferative Vitreoretinopathy. Ophthalmologica, 1991, 203, 38-46.	1.0	30
375	Class II histocompatibility antigen expression by cellular components of vitreous and subretinal fluid in proliferative vitreoretinopathy. Investigative Ophthalmology and Visual Science, 1991, 32, 2065-72.	3.3	18
376	Acidic Fibroblast Growth Factor Distribution in Normal Human Eye and Possible Implications in Ocular Pathogenesis. Ophthalmic Research, 1990, 22, 73-81.	1.0	25
377	HLA DR and DQ expression on human retinal pigment epithelial cells in vitro. Graefe's Archive for Clinical and Experimental Ophthalmology, 1990, 228, 86-89.	1.0	10
378	Immunohistologic Study of Epiretinal Membranes in Proliferative Vitreoretinopathy. American Journal of Ophthalmology, 1990, 110, 593-598.	1.7	62

#	Article	IF	CITATIONS
379	Class II Antigen Expression in Diabetic Preretinal Membranes. American Journal of Ophthalmology, 1990, 109, 70-74.	1.7	21
380	Detection of HBs antigen, DNA polymerase activity, and hepatitis B virus DNA in tears: relevance to hepatitis B transmission by tears British Journal of Ophthalmology, 1989, 73, 333-336.	2.1	15
381	Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye. Current Eye Research, 1989, 8, 1141-1152.	0.7	5
382	Ocular Manifestations of Drug Abuse. Cutaneous and Ocular Toxicology, 1989, 8, 291-307.	0.3	1
383	Immunohistologic Study of Proliferative Vitreoretinopathy. American Journal of Ophthalmology, 1989, 108, 387-394.	1.7	23
384	Immunohistopathologic Findings in Proliferative Diabetic Retinopathy. American Journal of Ophthalmology, 1988, 105, 383-388.	1.7	28
385	HLA DR and DQ distribution in normal human ocular structures. Current Eye Research, 1988, 7, 903-911.	0.7	38
386	Effects of aFGF and bFGF on wound healing in rabbit corneas. Current Eye Research, 1987, 6, 1205-1209.	0.7	87
387	The corneal endothelium in an endotoxin-induced uveitis model: Correlation between in vivo confocal microscopy and immunohistochemistry. Acta Ophthalmologica, 0, 86, 0-0.	0.6	3
388	The corneal module of the HRT-II: A new tool for assessing ocular inflammation. Acta Ophthalmologica, 0, 85, 0-0.	0.4	0
389	In vitro comparison of the oxidative and proapoptotic effects of preserved latanoprost, travoprost, bimatoprost and preservative-free tafluprost on conjunctival epithelial cells. Acta Ophthalmologica, 0, 85, 0-0.	0.4	0
390	Changes in ocular signs and symptoms when switching from preserved latanoprost 0.005% to preservative-free tafluprost 0.0015%: phase IIIb study in patients with open-angle glaucoma or ocular hypertension. Acta Ophthalmologica, 0, 86, 0-0.	0.6	0
391	Tufting enteropathy: ocular surface and conjunctival markers. Acta Ophthalmologica, 0, 86, 0-0.	0.6	Ο